Last 12 months
Inside the activity.
6 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 6 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2026 Filed Aug 26, 2026 21:08 UTC |
Potashnick RobertCAO & VP of Finance
|
GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0000914190-26-000137 · form4.xml · derivative · entry 3 Potashnick Robert · CIK 0001939454 · CAO & VP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2036-08-24 F2 · derivative.exercise_date: Options to purchase 62,500 shares vest on 8/24/2027, and 187,500 shares vest pro rata on the 24th of each month thereafter for 36 consecutive months. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 22:28 UTC |
Lucas Brent T.Director · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000100 · form4.xml · derivative · entry 8 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires 2030-06-18 F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Envoy Medical, Inc. Class A Common Stock. F8 · derivative.exercise_date: All restricted stock units subject to the RSU Award Grant Notice dated June 19, 2026, will vest as of the date of the official notification by the U.S. Food and Drug Administration (FDA) that it has granted approval (including approval with conditions) for its Acclaim cochlear implant, provided that such announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 22:28 UTC |
Lucas Brent T.Director · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000914190-26-000100 · form4.xml · derivative · entry 4 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires 2036-06-19 F3 · derivative.exercise_date: Options to purchase 250,000 shares vest on 6/19/27, and 750,000 shares vest pro rata on the 19th of each month thereafter for 36 consecutive months. Read SEC document |
| May 29, 2026 Filed Jun 4, 2026 20:28 UTC |
Lucas Brent T.Director · Chief Executive Officer
|
GrantClass A Common Stock | 32,856 | $0.60 | $19,680.74 |
DisclosureSEC source: 0000914190-26-000095 · form4.xml · nonDerivative · entry 1 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,946 F1 · kind: These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:32 UTC |
McKhann ChasDirector
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000914190-26-000077 · form4.xml · derivative · entry 1 McKhann Chas · CIK 0001631746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2036-04-15 F1 · derivative.exercise_date: Beginning on 5/15/2026, options to purchase Class A Common Stock will vest pro rata on the 15th of each month for 36 consecutive months. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:49 UTC |
Potashnick RobertInterim CFO
|
PurchaseWarrant (right to buy) · Derivative | 212,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000027 · form4.xml · derivative · entry 4 Potashnick Robert · CIK 0001939454 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,500 Underlying: Class A Common Stock · 212,500 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F4 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:49 UTC |
Potashnick RobertInterim CFO
|
PurchaseWarrant (right to buy) · Derivative | 127,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000027 · form4.xml · derivative · entry 3 Potashnick Robert · CIK 0001939454 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,500 Underlying: Class A Common Stock · 127,500 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F3 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:49 UTC |
Potashnick RobertInterim CFO
|
PurchaseClass A Common Stock | 212,500 | $0.40 | $85,000.00 |
DisclosureSEC source: 0000914190-26-000027 · form4.xml · nonDerivative · entry 1 Potashnick Robert · CIK 0001939454 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,500 Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:47 UTC |
Kantor SusanDirector
|
PurchaseWarrant (right to buy) · Derivative | 96,150 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000026 · form4.xml · derivative · entry 5 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,150 Underlying: Class A Common Stock · 96,150 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F4 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:47 UTC |
Kantor SusanDirector
|
PurchaseWarrant (right to buy) · Derivative | 57,690 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000026 · form4.xml · derivative · entry 4 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,690 Underlying: Class A Common Stock · 57,690 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F3 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:47 UTC |
Kantor SusanDirector
|
PurchaseClass A Common Stock | 96,150 | $0.40 | $38,460.00 |
DisclosureSEC source: 0000914190-26-000026 · form4.xml · nonDerivative · entry 1 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,037 Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 13:35 UTC |
TAYLOR GLEN A10% owner
|
PurchaseWarrant Shares (Series A-2) · Derivative | 18,750,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001104659-26-016182 · tm266585-1_4seq1.xml · derivative · entry 5 TAYLOR GLEN A · CIK 0001213971 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750,000 Underlying: Class A Common Stock · 18,750,000 shares Expires not disclosed F3 · derivative.exercise_date: The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date"). F5 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event"). Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 13:35 UTC |
TAYLOR GLEN A10% owner
|
PurchaseWarrant Shares (Series A-1) · Derivative | 11,250,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001104659-26-016182 · tm266585-1_4seq1.xml · derivative · entry 4 TAYLOR GLEN A · CIK 0001213971 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250,000 Underlying: Class A Common Stock · 11,250,000 shares Expires not disclosed F3 · derivative.exercise_date: The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date"). F4 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event"). Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 13:35 UTC |
TAYLOR GLEN A10% owner
|
PurchaseClass A Common Stock | 18,750,000 | $0.40 | $7,500,000.00 |
DisclosureSEC source: 0001104659-26-016182 · tm266585-1_4seq1.xml · nonDerivative · entry 3 TAYLOR GLEN A · CIK 0001213971 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,703,607 Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:45 UTC |
BRYNELSEN CHARLESDirector
|
PurchaseWarrant (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000025 · form4.xml · derivative · entry 5 BRYNELSEN CHARLES · CIK 0001712459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F4 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:45 UTC |
BRYNELSEN CHARLESDirector
|
PurchaseWarrant (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000025 · form4.xml · derivative · entry 4 BRYNELSEN CHARLES · CIK 0001712459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Class A Common Stock · 600,000 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F3 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:45 UTC |
BRYNELSEN CHARLESDirector
|
PurchaseClass A Common Stock | 1,000,000 | $0.40 | $400,000.00 |
DisclosureSEC source: 0000914190-26-000025 · form4.xml · nonDerivative · entry 1 BRYNELSEN CHARLES · CIK 0001712459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,000 Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:51 UTC |
Patel Mona ChetanDirector
|
PurchaseWarrant (right to buy) · Derivative | 312,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000028 · form4.xml · derivative · entry 5 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,500 Underlying: Class A Common Stock · 312,500 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F4 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:51 UTC |
Patel Mona ChetanDirector
|
PurchaseWarrant (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000028 · form4.xml · derivative · entry 4 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,500 Underlying: Class A Common Stock · 187,500 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F3 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:51 UTC |
Patel Mona ChetanDirector
|
PurchaseClass A Common Stock | 312,500 | $0.40 | $125,000.00 |
DisclosureSEC source: 0000914190-26-000028 · form4.xml · nonDerivative · entry 1 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,500 Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:45 UTC |
Lucas Brent T.Director · Chief Executive Officer
|
PurchaseWarrant (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000024 · form4.xml · derivative · entry 6 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Class A Common Stock · 62,500 shares Expires not disclosed F4 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F6 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:45 UTC |
Lucas Brent T.Director · Chief Executive Officer
|
PurchaseWarrant (right to buy) · Derivative | 37,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000024 · form4.xml · derivative · entry 5 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Class A Common Stock · 37,500 shares Expires not disclosed F4 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F5 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:45 UTC |
Lucas Brent T.Director · Chief Executive Officer
|
PurchaseClass A Common Stock | 62,500 | $0.40 | $25,000.00 |
DisclosureSEC source: 0000914190-26-000024 · form4.xml · nonDerivative · entry 1 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,090 Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:45 UTC |
Potashnick RobertInterim CFO
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0000914190-26-000015 · form4.xml · derivative · entry 1 Potashnick Robert · CIK 0001939454 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2036-02-05 F1 · derivative.exercise_date: Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:45 UTC |
Lucas Brent T.Director · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0000914190-26-000014 · form4.xml · derivative · entry 4 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Class A Common Stock · 200,000 shares Expires 2036-02-05 F3 · derivative.exercise_date: Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 17:42 UTC |
Crowe Michael CurtisDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000914190-25-000051 · form4.xml · derivative · entry 2 Crowe Michael Curtis · CIK 0002026683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2035-12-03 Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 17:40 UTC |
Kantor SusanDirector
|
GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000914190-25-000049 · form4.xml · derivative · entry 3 Kantor Susan · CIK 0001673071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Class A Common Stock · 62,500 shares Expires 2035-12-03 Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 17:40 UTC |
BRYNELSEN CHARLESDirector
|
GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000914190-25-000048 · form4.xml · derivative · entry 3 BRYNELSEN CHARLES · CIK 0001712459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Class A Common Stock · 62,500 shares Expires 2035-12-03 Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 22:42 UTC |
Smith-Gomez JanisDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000914190-25-000052 · form4.xml · derivative · entry 2 Smith-Gomez Janis · CIK 0001995670 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2035-12-03 Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 22:41 UTC |
Patel Mona ChetanDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000914190-25-000050 · form4.xml · derivative · entry 3 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2035-12-03 Read SEC document |
| November 28, 2025 Filed Dec 10, 2025 22:49 UTC |
Lucas Brent T.Director · Chief Executive Officer
|
GrantClass A Common Stock | 18,105 | $0.71 | $12,908.87 |
DisclosureSEC source: 0000914190-25-000054 · form4.xml · nonDerivative · entry 1 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,590 F1 · kind: These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
GrantWarrant (right to buy) · Derivative | 750,000 | Not disclosed Strike: $1.48 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 18 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2028-12-31 F11 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable. F11 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
Disposition to issuerWarrant (right to buy) · Derivative | 750,000 | Not disclosed Strike: $1.48 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 17 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 750,000 shares Expires 2027-06-26 F11 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable. F11 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 6/26/2025 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
GrantWarrant (right to buy) · Derivative | 750,000 | Not disclosed Strike: $1.35 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 16 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2028-12-31 F10 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable. F10 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
Disposition to issuerWarrant (right to buy) · Derivative | 750,000 | Not disclosed Strike: $1.35 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 15 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 750,000 shares Expires 2028-03-11 F10 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable. F10 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 3/11/2025 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
GrantWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.20 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 14 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2028-12-31 F9 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable. F9 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
Disposition to issuerWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.20 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 13 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 500,000 shares Expires 2026-08-27 F9 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable. F9 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 12/11/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
GrantWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.97 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 12 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2028-12-31 F8 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable. F8 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
Disposition to issuerWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.97 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 11 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 500,000 shares Expires 2026-08-27 F8 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable. F8 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 8/27/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
GrantWarrant (right to buy) · Derivative | 250,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 10 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2028-12-31 F7 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable. F7 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
Disposition to issuerWarrant (right to buy) · Derivative | 250,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 9 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 250,000 shares Expires 2026-02-27 F7 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable. F7 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 7/22/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
GrantWarrant (right to buy) · Derivative | 250,000 | Not disclosed Strike: $3.04 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 8 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2028-12-31 F6 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable. F6 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
Disposition to issuerWarrant (right to buy) · Derivative | 250,000 | Not disclosed Strike: $3.04 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 7 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 250,000 shares Expires 2026-02-27 F6 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable. F6 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally granted on 5/23/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
GrantWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $1.24 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 6 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2028-12-31 F4 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable. F4 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 17:17 UTC |
TAYLOR GLEN ADirector · 10% owner
|
Disposition to issuerWarrant (right to buy) · Derivative | 500,000 | Not disclosed Strike: $1.24 | Not disclosed |
DisclosureSEC source: 0001062993-25-015411 · form4.xml · derivative · entry 5 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 0 Underlying: Class A Common Stock · 500,000 shares Expires 2026-02-27 F4 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable. F4 · price: The two reported transactions involved an amendment of an outstanding warrant, resulting in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally purchased on 2/27/2024 and is fully exercisable. F5 · derivative.exercise_date: Fully exercisable. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| June 26, 2025 Filed Jul 8, 2025 10:37 UTC |
TAYLOR GLEN ADirector · 10% owner
|
GrantWarrant (right to buy) · Derivative | 750,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001062993-25-012617 · form4.xml · derivative · entry 11 TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · GAT Funding, LLC Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2027-06-26 F4 · shares: In connection with the promissory note issuance effective March 6, 2025 and the closing of the final funding on June 26, 2025, this warrant was issued to GAT Funding, LLC, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on July 2, 2025. F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:10 UTC |
Patel Mona ChetanDirector
|
PurchaseClass A Common Stock | 2,500 | $1.47 | $3,675.00 |
DisclosureSEC source: 0001062993-25-011661 · form4.xml · nonDerivative · entry 1 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.44 to $1.4799 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:11 UTC |
Patel Mona ChetanDirector
|
PurchaseClass A Common Stock | 10,000 | $1.46 | $14,600.00 |
DisclosureSEC source: 0001062993-25-011320 · form4.xml · nonDerivative · entry 1 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.4981 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 30, 2025 Filed Jun 10, 2025 00:58 UTC |
Lucas Brent T.Director · Chief Executive Officer
|
GrantClass A Common Stock | 7,742 | $1.29 | $10,008.08 |
DisclosureSEC source: 0001062993-25-011296 · form4.xml · nonDerivative · entry 2 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,485 F1 · kind: These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 27, 2025 Filed May 27, 2025 18:34 UTC |
BRYNELSEN CHARLESDirector
|
PurchaseClass A Common Stock | 35,000 | $1.65 | $57,673.00 |
DisclosureSEC source: 0001062993-25-010396 · form4.xml · nonDerivative · entry 3 BRYNELSEN CHARLES · CIK 0001712459 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6345 to $1.65 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.